Symbols / AEON
AEON Chart
About
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 31.38M |
| Enterprise Value | 27.01M | Income | -3.00K | Sales | — |
| Book/sh | -1.71 | Cash/sh | 0.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | 0.42 | Forward P/E | -1.80 | PEG | — |
| P/S | — | P/B | -0.73 | P/C | — |
| EV/EBITDA | -1.61 | EV/Sales | — | Quick Ratio | 0.72 |
| Current Ratio | 0.90 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 2.98 | EPS next Y | -0.69 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -165.52% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 25.30M |
| Shs Float | 4.59M | Short Float | 1.06% | Short Ratio | 0.89 |
| Short Interest | — | 52W High | 8.93 | 52W Low | 0.38 |
| Beta | 0.72 | Avg Volume | 185.44K | Volume | 91.14K |
| Target Price | $5.20 | Recom | None | Prev Close | $1.26 |
| Price | $1.24 | Change | -1.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.20
Mean price target
2. Current target
$1.22
Latest analyst target
3. DCF / Fair value
$-5.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.22
Low
$5.00
High
$5.40
Mean
$5.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-08 | reit | Aegis Capital | Buy → Buy | $7 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-14 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-08-18 | init | HC Wainwright & Co. | — → Buy | $18 |
- Pre-market JPX 25 Feb 2026: 9787.T Aeon Delight at JPY 5380.00 — oversold bounce watch - Meyka ue, 24 Feb 2026 15
- AEON Biopharma (NYSE: AEON) agrees Daewoong swap cutting over 90% of debt - Stock Titan Mon, 15 Dec 2025 08
- AEON Financial Service Delays Effective Date of Merger With AFS Corporation - The Globe and Mail Sat, 21 Feb 2026 08
- Aeon Co. (M) Bhd.'s (KLSE:AEON) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - Yahoo Finance Sun, 28 Sep 2025 07
- AEON Biopharma (AEON) Price Target Decreased by 15.28% to 6.22 - Nasdaq Fri, 05 Dec 2025 08
- Earnings call transcript: Aeon Q3 2025 misses EPS forecast, stock drops - Investing.com ue, 03 Feb 2026 08
- A family fights to keep control of 157-year-old firm in Japan - The Japan Times Mon, 16 Feb 2026 01
- Midday Stock Roundup: MDxHealth Up 9% Since Preliminary Q4, FY Results - Orange County Business Journal hu, 22 Jan 2026 18
- Why AEON stock remains on buy lists - Treasury Yields & Consistent Growth Stock Picks - mfd.ru Fri, 20 Feb 2026 21
- Shareholders back AEON debt-cut deals after FDA meeting on Botox biosimilar - Stock Titan Wed, 21 Jan 2026 08
- Close JPY 5,380.00: Aeon Delight (9787.T JPX) Market Closed 20 Feb 2026, Oversold bounce watch - Meyka Fri, 20 Feb 2026 14
- Aeon Biopharma stock falls after FDA meeting and debt restructuring - Investing.com Wed, 21 Jan 2026 08
- Investors in Aeon (M) Bhd (KLSE:AEON) have unfortunately lost 24% over the last year - Yahoo Finance Sun, 14 Dec 2025 08
- 8267.T Stock Today: Aeon Big Reopens ‘The Big Express’ Shizuoka, February 12 - Meyka Wed, 11 Feb 2026 18
- Are Investors Undervaluing Aeon Co. (M) Bhd. (KLSE:AEON) By 39%? - Yahoo Finance Wed, 06 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 60000 | 29250.0 | — | Purchase at price 0.49 per share. | FISCHER JOST | Director | — | 2025-05-21 00:00:00 | D |
| 1 | 110000 | 55300.0 | — | Purchase at price 0.50 - 0.51 per share. | FISCHER JOST | Director | — | 2025-05-20 00:00:00 | D |
| 2 | 177103 | — | — | Stock Award(Grant) at price 0.00 per share. | BANCROFT ROBERT E. | Chief Executive Officer | — | 2025-05-14 00:00:00 | D |
| 3 | 36021 | — | — | Stock Award(Grant) at price 0.00 per share. | PALMISANO ROBERT J | Director | — | 2024-08-30 00:00:00 | D |
| 4 | 36021 | nan | — | — | PALMISANO ROBERT J | Director | — | 2024-08-30 00:00:00 | D |
| 5 | 36021 | nan | — | — | THUNEN SHELLEY B | Director | — | 2024-08-30 00:00:00 | D |
| 6 | 36021 | nan | — | — | FISCHER JOST | Director | — | 2024-08-30 00:00:00 | D |
| 7 | 36021 | nan | — | — | CARTER ERIC G | Director | — | 2024-08-30 00:00:00 | D |
| 8 | 470692 | nan | — | — | FORTH MARC | Chief Executive Officer | — | 2024-08-30 00:00:00 | D |
| 9 | 180110 | nan | — | — | WILSON ALEXANDER BLAIR | Officer | — | 2024-08-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | |
| NormalizedEBITDA | -97.46M | -43.95M | -8.71M | |
| TotalUnusualItems | 69.73M | -4.42M | -28.17M | |
| TotalUnusualItemsExcludingGoodwill | 69.73M | -4.42M | -28.17M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | 42.01M | -52.56M | -55.64M | |
| ReconciledDepreciation | 97.00K | 68.00K | 3.00K | |
| EBITDA | -27.73M | -48.36M | -36.88M | |
| EBIT | -27.82M | -48.43M | -36.88M | |
| NormalizedIncome | -27.73M | -48.14M | -27.47M | |
| NetIncomeFromContinuingAndDiscontinuedOperation | 42.01M | -52.56M | -55.64M | |
| TotalExpenses | 27.82M | 48.43M | 36.88M | |
| TotalOperatingIncomeAsReported | 72.98M | -48.43M | -65.85M | |
| DilutedAverageShares | 575.95K | 516.11K | 305.50K | 305.50K |
| BasicAverageShares | 540.36K | 516.11K | 305.50K | 305.50K |
| DilutedEPS | 72.93 | -172.03 | -182.12 | |
| BasicEPS | 77.74 | -172.03 | -182.12 | |
| DilutedNIAvailtoComStockholders | 42.01M | -52.56M | -55.64M | |
| NetIncomeCommonStockholders | 42.01M | -52.56M | -55.64M | |
| NetIncome | 42.01M | -52.56M | -55.64M | |
| NetIncomeIncludingNoncontrollingInterests | 42.01M | -52.56M | -55.64M | |
| NetIncomeContinuousOperations | 42.01M | -52.56M | -55.64M | |
| TaxProvision | 0.00 | 0.00 | 0.00 | |
| PretaxIncome | 42.01M | -52.56M | -55.64M | |
| OtherIncomeExpense | 69.83M | -4.13M | -18.76M | |
| OtherNonOperatingIncomeExpenses | 95.00K | 289.00K | 9.41M | |
| SpecialIncomeCharges | 100.81M | 0.00 | -28.97M | |
| OtherSpecialCharges | 28.97M | |||
| RestructuringAndMergernAcquisition | -100.81M | 0.00 | ||
| GainOnSaleOfSecurity | -31.07M | -4.42M | 795.00K | |
| OperatingIncome | -27.82M | -48.43M | -36.88M | |
| OperatingExpense | 27.82M | 48.43M | 36.88M | |
| ResearchAndDevelopment | 14.18M | 34.75M | 25.73M | |
| SellingGeneralAndAdministration | 13.64M | 13.68M | 11.15M | |
| TotalRevenue | 0.00 | 0.00 | 0.00 | |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 555.51K | 516.11K | 380.98K | 380.98K |
| ShareIssued | 555.51K | 516.11K | 380.98K | 380.98K |
| NetDebt | 11.68M | 121.55M | 81.24M | |
| TotalDebt | 12.96M | 278.00K | 131.79M | 86.89M |
| TangibleBookValue | -28.57M | -153.04M | -287.50M | -234.94M |
| InvestedCapital | -16.88M | -153.04M | -156.21M | -148.58M |
| WorkingCapital | -12.56M | -6.83M | -72.74M | -15.65M |
| NetTangibleAssets | -28.57M | -153.04M | -287.50M | -234.94M |
| CapitalLeaseObligations | 1.27M | 278.00K | 499.00K | 524.00K |
| CommonStockEquity | -28.57M | -153.04M | -287.50M | -234.94M |
| TotalCapitalization | -16.88M | -153.04M | -227.07M | -164.18M |
| TotalEquityGrossMinorityInterest | -28.57M | -153.04M | -270.41M | -223.82M |
| MinorityInterest | 0.00 | 0.00 | 17.09M | 11.12M |
| StockholdersEquity | -28.57M | -153.04M | -287.50M | -234.94M |
| OtherEquityInterest | -60.71M | |||
| TreasuryStock | 0.00 | 0.00 | 23.00K | 23.00K |
| RetainedEarnings | -431.60M | -473.60M | -474.84M | -422.28M |
| AdditionalPaidInCapital | 403.02M | 381.26M | 187.35M | 187.35M |
| CapitalStock | 4.00K | 4.00K | 14.00K | 14.00K |
| CommonStock | 4.00K | 4.00K | 14.00K | 14.00K |
| TotalLiabilitiesNetMinorityInterest | 31.71M | 159.89M | 281.19M | 230.26M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.56M | 146.84M | 198.62M | 209.46M |
| OtherNonCurrentLiabilities | 3.54M | 104.35M | 221.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | 137.95M | 137.95M |
| DerivativeProductLiabilities | 1.19M | 42.49M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 12.83M | 0.00 | 60.67M | 71.29M |
| LongTermCapitalLeaseObligation | 1.15M | 0.00 | 242.00K | 524.00K |
| LongTermDebt | 11.69M | 60.43M | 70.76M | |
| CurrentLiabilities | 14.15M | 13.05M | 82.57M | 20.80M |
| CurrentDebtAndCapitalLeaseObligation | 121.00K | 278.00K | 71.12M | 15.60M |
| CurrentCapitalLeaseObligation | 121.00K | 278.00K | 257.00K | |
| CurrentDebt | 70.87M | 15.60M | ||
| OtherCurrentBorrowings | 70.87M | 15.60M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.07M | 943.00K | 1.11M | 1.07M |
| PayablesAndAccruedExpenses | 12.96M | 11.83M | 10.34M | 4.13M |
| CurrentAccruedExpenses | 6.48M | 7.87M | 2.53M | 2.94M |
| Payables | 6.48M | 3.96M | 7.80M | 1.19M |
| TotalTaxPayable | 569.00K | 569.00K | 0.00 | |
| AccountsPayable | 5.91M | 3.39M | 7.80M | 1.19M |
| TotalAssets | 3.14M | 6.84M | 10.78M | 6.44M |
| TotalNonCurrentAssets | 1.55M | 623.00K | 940.00K | 1.28M |
| OtherNonCurrentAssets | 29.00K | 29.00K | 34.00K | 360.00K |
| NetPPE | 1.52M | 594.00K | 906.00K | 922.00K |
| AccumulatedDepreciation | -267.00K | -170.00K | -71.00K | -3.00K |
| GrossPPE | 1.79M | 764.00K | 977.00K | 925.00K |
| Leases | 66.00K | 66.00K | 66.00K | 66.00K |
| OtherProperties | 237.00K | 237.00K | 237.00K | 729.00K |
| MachineryFurnitureEquipment | 199.00K | 199.00K | 199.00K | 130.00K |
| BuildingsAndImprovements | 1.29M | 262.00K | 475.00K | 729.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.59M | 6.22M | 9.84M | 5.15M |
| OtherCurrentAssets | 1.58M | 1.06M | 92.00K | 26.00K |
| CashCashEquivalentsAndShortTermInvestments | 13.00K | 5.16M | 9.75M | 5.13M |
| CashAndCashEquivalents | 13.00K | 5.16M | 9.75M | 5.13M |
| CashFinancial | 5.16M | 9.75M | 5.13M |
| Line Item | 2024-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -20.29M | -35.89M | -28.60M |
| RepaymentOfDebt | -3.99M | 0.00 | |
| IssuanceOfDebt | 15.00M | 44.50M | 15.00M |
| IssuanceOfCapitalStock | 147.00K | ||
| CapitalExpenditure | -306.00K | -170.00K | |
| EndCashPosition | 13.00K | 9.75M | 5.13M |
| BeginningCashPosition | 5.16M | 5.13M | 20.17M |
| ChangesInCash | -5.14M | 4.62M | -15.04M |
| FinancingCashFlow | 15.15M | 40.51M | 13.56M |
| CashFlowFromContinuingFinancingActivities | 15.15M | 40.51M | 13.56M |
| NetOtherFinancingCharges | -1.44M | ||
| NetCommonStockIssuance | 147.00K | ||
| CommonStockIssuance | 147.00K | ||
| NetIssuancePaymentsOfDebt | 15.00M | 40.51M | 15.00M |
| NetLongTermDebtIssuance | 15.00M | 40.51M | 15.00M |
| LongTermDebtPayments | -3.99M | 0.00 | |
| LongTermDebtIssuance | 15.00M | 44.50M | 15.00M |
| InvestingCashFlow | 0.00 | -306.00K | -170.00K |
| CashFlowFromContinuingInvestingActivities | -306.00K | -170.00K | |
| NetPPEPurchaseAndSale | -306.00K | -170.00K | |
| PurchaseOfPPE | -306.00K | -170.00K | |
| OperatingCashFlow | -20.29M | -35.58M | -28.43M |
| CashFlowFromContinuingOperatingActivities | -20.29M | -35.58M | -28.43M |
| ChangeInWorkingCapital | 706.00K | 6.27M | 1.42M |
| ChangeInOtherWorkingCapital | 120.00K | -174.00K | -26.00K |
| ChangeInPayablesAndAccruedExpense | 1.10M | 6.51M | 1.26M |
| ChangeInAccruedExpense | -1.42M | -105.00K | 2.16M |
| ChangeInPayable | 2.52M | 6.61M | -898.00K |
| ChangeInAccountPayable | 2.52M | 6.61M | -898.00K |
| ChangeInPrepaidAssets | -513.00K | -66.00K | 182.00K |
| OtherNonCashItems | -103.74M | 4.41M | 18.59M |
| StockBasedCompensation | 6.25M | 5.89M | 5.22M |
| UnrealizedGainLossOnInvestmentSecurities | 4.42M | -795.00K | |
| AssetImpairmentCharge | 331.00K | 1.98M | |
| DepreciationAmortizationDepletion | 97.00K | 68.00K | 3.00K |
| DepreciationAndAmortization | 97.00K | 68.00K | 3.00K |
| Depreciation | 97.00K | 68.00K | 3.00K |
| OperatingGainsLosses | 34.39M | ||
| GainLossOnInvestmentSecurities | 34.39M | ||
| NetIncomeFromContinuingOperations | 42.01M | -52.56M | -55.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AEON
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|